hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06350487 id: SMC2024-01-089-003 briefTitle: The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction acronym: ENRICH-PEF overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2025-12-31 date: 2026-06-30 date: 2024-04-05 date: 2024-04-08 name: Samsung Medical Center class: OTHER briefSummary: The aim of prospective, open label, single center, randomized controlled trial is to investigate the efficacy of enavogliflozin on exercise performance, diastolic dysfunction, and quality of life in patients with heart failure with preserved ejection fraction (HFpEF). conditions: Heart Failure, Preserved Ejection Fraction studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A prospective, open label, single center, randomized controlled trial. primaryPurpose: TREATMENT masking: SINGLE maskingDescription: Clinical outcome assessment will be performed under blinded assessment about the allocated treatment group. whoMasked: OUTCOMES_ASSESSOR count: 154 type: ESTIMATED name: SGLT2 inhibitor measure: Change in peak oxygen consumption (VO2) measure: Change in minute ventilation to carbon dioxide output ratio (VE/VCO2 slope) measure: Change in Left atrial volume index (LAVI) before and after maximal exercise measure: Change in Lateral Early diastolic transmitral filling velocity over early diastolic relaxation velocity at mitral annulus (E/e') before and after maximal exercise measure: Change in Left ventricular mass index (LVMI) before and after maximal exercise measure: Change in LV wall thickness before and after maximal exercise measure: Change in LV global longitudinal strain before and after maximal exercise measure: Change in LA strain before and after maximal exercise measure: Change in right ventricular (RV) free wall strain before and after maximal exercise measure: Change in health-related quality of life assessed by the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CS) measure: Change in N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP) level measure: Change in chronotropic response reserve assessed by change in heart rate from rest to peak exercise measure: Change in serum iron measure: Change in ferritin measure: Change in total iron binding capacity measure: Change in hemoglobin measure: All-cause death measure: Hospitalization for heart failure sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Samsung Medical Center city: Seoul zip: 06351 country: Korea, Republic of name: Jeong Hoon Yang, MD, PhD role: CONTACT phone: 82-2-3410-3419 email: jhysmc@gmail.com name: David Hong, MD role: CONTACT phone: 82-2-3410-3419 email: hongdawi@naver.com lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06350474 id: SIMPLIFY-IP-19 Dnase briefTitle: Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study acronym: SIMPLIFY-DN overallStatus: COMPLETED date: 2020-08-25 date: 2022-07-11 date: 2022-07-11 date: 2024-04-05 date: 2024-04-05 name: Nicole Hamblett class: OTHER name: Cystic Fibrosis Foundation name: Dartmouth-Hitchcock Medical Center name: University of Washington briefSummary: Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking dornase alfa (Dnase) in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI).
nctId: NCT06350461 id: SIMPLIFY-IP-19 HS briefTitle: Impact of Discontinuing Hypertonic Saline in People With CF on Highly Effective CFTR Modulators- A SIMPLIFY Sub-Study acronym: SIMPLIFY-HS overallStatus: COMPLETED date: 2020-08-25 date: 2022-07-11 date: 2022-07-11 date: 2024-04-05 date: 2024-04-05 name: Nicole Hamblett class: OTHER name: Cystic Fibrosis Foundation name: Dartmouth-Hitchcock Medical Center name: University of Washington briefSummary: Despite the increasingly common use of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies in treating cystic fibrosis (CF), it is still largely unknown whether or not other chronic therapies can be safely stopped. This SIMPLIFY sub-study is being done to test whether or not it is safe to stop taking inhaled hypertonic saline in those people that are also taking elexacaftor/tezacaftor/ivacaftor (ETI).
nctId: NCT06350448 id: WMT-CN-RH briefTitle: Washed Microbiota Transplantation for Rhinitis overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2029-05-01 date: 2029-08-01 date: 2024-04-05 date: 2024-04-05 name: The Second Hospital of Nanjing Medical University class: OTHER briefSummary: The common symptoms of rhinitis include nasal itching, sneezing, anterior or posterior nasal leakage, and nasal congestion. Rhinitis can be classified as allergic rhinitis (AR) and non-allergic rhinitis (NAR) based on the presence of a specific allergen. Increasing evidence showed that gut microbiota can influence the development of AR. Although few studies have reported the association between NAR and gut microbiota, we found that washed microbiota transplantation (WMT) could improve nasal symptoms, whether it is AR or NAR. This clinical trial aims to evaluate the efficacy and safety of WMT for rhinitis. conditions: Rhinitis studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Washed Microbiota Transplantation measure: Changes in the reflective total nasal symptom score (rTNSS) measure: Changes in the combined symptoms and medication score (CSMS) measure: Changes in the rhinoconjunctivitis quality of life questionnaire (RQLQ) score measure: Changes in the single reflective nasal symptoms score measure: Specific IgE measure: Inflammatory factors measure: Flow cytometric analysis of lymphocyte clusters measure: The incidence of treatment-related adverse events (AE) assessed by CTCAE, Version 5.0 sex: ALL minimumAge: 6 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University city: Nanjing state: Jiangsu zip: 210011 country: China name: Faming Zhang, MD,PhD role: CONTACT phone: 086-25-58509883 email: fzhang@njmu.edu.cn lat: 32.06167 lon: 118.77778 hasResults: False
nctId: NCT06350435 id: CUHK 2023.569 briefTitle: Effects of Prefabricated Foot Orthoses With and Without Metatarsal Pads on Central Metatarsalgia overallStatus: ACTIVE_NOT_RECRUITING date: 2023-12-18 date: 2024-04-26 date: 2024-05-31 date: 2024-04-05 date: 2024-04-05 name: Chinese University of Hong Kong class: OTHER name: Pamela Youde Nethersole Eastern Hospital briefSummary: Compare the effects of prefabricated foot orthoses with and without metatarsal pads on pain intensity in the 2nd to 4th metatarsophalangeal joints, foot and ankle functional abilities as well as the occurrence of plantar callosities among patients with central metatarsalgia. conditions: Metatarsalgia studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 32 type: ACTUAL name: Prefabricated foot orthoses (PFO) with metatarsal pads name: Prefabricated foot orthoses (PFO) without metatarsal pads measure: Pain intensity at the 2nd to 4th metatarsophalangeal joints during walking in shoes on Visual Analogue Scale measure: Foot and Ankle Outcome Score measure: Size of callosities and corns on the plantar area of the 2nd to 4th metatarsophalangeal joints sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pamela Youde Nethersole Eastern Hospital city: Hong Kong country: Hong Kong lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06350422 id: Microgravity-ChinaPLAGH briefTitle: Neuroimage Genome Study of Neuroplasticity Associated With Microgravity overallStatus: ACTIVE_NOT_RECRUITING date: 2022-01-01 date: 2024-10-31 date: 2024-12-31 date: 2024-04-05 date: 2024-04-05 name: Chinese PLA General Hospital class: OTHER briefSummary: This clinical trial investigates the neuroplasticity and cognitive status changes of the human brain in microgravity. To explore the relationship between cognitive status changes and brain functional activities, gray matter and white matter changes under microgravity exposure, screen and identify representative image markers, so as to provide decision-making information for the cognitive status changes of relevant personnel under microgravity environment. conditions: Microgravity conditions: Neuroplasticity conditions: MRI conditions: Repeatable Battery for the Assessment of Neuropsychological Status studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 26 type: ACTUAL name: Head-Down tilt Bed Rest test measure: Local brain functional activity measure: Brain functional connectivity measure: Brain structure - Morphology measure: Brain fiber bundle and brain Diffusion index measure: Brain blood flow measure: Imaging indexes and clinical scale scores sex: MALE minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Chinese PLA General Hospital city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06350409 id: CTN-0146 id: UG1DA015831-22S4 type: NIH link: https://reporter.nih.gov/quickSearch/UG1DA015831-22S4 briefTitle: Adolescent Outcomes of Post-operative Opioid EXposure acronym: APEX overallStatus: NOT_YET_RECRUITING date: 2024-08-10 date: 2026-09-10 date: 2026-10-10 date: 2024-04-05 date: 2024-04-10 name: Sharon Levy class: OTHER name: National Institute on Drug Abuse (NIDA) name: National Institutes of Health (NIH) briefSummary: The goal of this observational study is to examine the factors associated with the transition from medical exposure to opioids with "signposts" of future opioid use disorder among adolescent surgical patients. The main question aims to identify factors (moderators, mediators, and covariates) associated with risk factors for opioid use disorder (ROUD) in the 12 months following major surgery with opioid exposure among adolescents aged 12-17. Participants will be asked to complete electronic surveys pre- and post-operatively and approve the collection of peri-operative data from the Electronic Medical Record to assess correlations. conditions: Opioid Use Disorder conditions: Pain, Chronic studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 20000 type: ESTIMATED measure: Risk of opioid use disorder due to prolonged pain that develops within the first year after surgery. measure: Risk of opioid use disorder due to prolonged opioid use that develops within the first year after surgery. measure: Risk of opioid use disorder due to postoperative non-medical use of prescription opioids (NMUPO) that develops within the first year after surgery. measure: Risk of opioid use disorder due to increased rate of change in substance use that develops within the first year after surgery. measure: Risk of opioid use disorder due to post-surgical trauma that develops within the first year after surgery. sex: ALL minimumAge: 12 Years maximumAge: 17 Years stdAges: CHILD facility: Boston Childrens Hopsital - Division of Addiction Medicine city: Boston state: Massachusetts zip: 02115 country: United States name: Melissa Brogna, MSW role: CONTACT phone: 857-218-4311 email: Melissa.Brogna@childrens.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06350396 id: CPLTRDDM2024 briefTitle: pBFS-guided rTMS Over DMPFC for Treatment-Resistant Depression overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12-30 date: 2025-06-30 date: 2024-04-05 date: 2024-04-05 name: Changping Laboratory class: OTHER briefSummary: This study is a multicenter, randomized, double-blind, placebo-controlled trial aimed at exploring the effectiveness and safety of rTMS intervention with DMPFC targets guided by pBFS in patients with treatment-resistant depression. conditions: Treatment Resistant Depression conditions: Major Depressive Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 270 type: ESTIMATED name: active rTMS treatment name: sham rTMS treatment measure: Change in Montgomery-Asberg Depression Rating Scale (MADRS) scores from baseline to Immediate Post-treatment measure: Remission and response rates were estimated using Montgomery-Asberg Depression Rating Scale(MADRS) measure: Remission and response rates were estimated using Hamilton Depression Rating Scale (HAMD-17) measure: Changes in the MADRS from baseline to each visit measure: Changes in the HAMD-17 from baseline to each visit measure: cognitive change in Digit Symbol Substitution Test (DSST) measure: cognitive change in continuous performance test (CPT) measure: cognitive change in Trail-Making Test (TMT) measure: cognitive change in Digit Span Test (DST) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hebei Mental Health Center city: Hebei state: Baoding country: China name: Lili Zhang role: CONTACT facility: West China Hospital, Sichuan University city: Chengdu country: China name: Qiyong Gong role: CONTACT lat: 30.66667 lon: 104.06667 facility: Inner Mongolia Mental Health Center city: Hohhot country: China name: Dongsheng Lv role: CONTACT lat: 40.81056 lon: 111.65222 facility: Shandong Daizhuang Hospital city: Jining country: China name: Zhonggang Wang role: CONTACT lat: 35.405 lon: 116.58139 facility: The Second Affiliated Hospital of Xinxiang Medical University city: Xinxiang country: China name: Yongfeng Yang role: CONTACT lat: 35.19033 lon: 113.80151 hasResults: False
nctId: NCT06350370 id: NCC3489 briefTitle: Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study overallStatus: RECRUITING date: 2019-01-01 date: 2023-01-01 date: 2028-01-01 date: 2024-04-05 date: 2024-04-05 name: Cancer Institute and Hospital, Chinese Academy of Medical Sciences class: OTHER briefSummary: Natural orifice specimen extraction surgery (NOSES) has gained widespread recognition among scholars and has gradually been promoted and popularized around the world. However, the development of NOSES is still in the exploratory stage and there is a lack of strong evidence from evidence-based medicine to support its feasibility and safety, which has greatly affected its clinical application and development. Based on this, at the call of Professor Xishan Wang, the Chinese NOSES Alliance conducted a large retrospective clinical study involving multiple centers. By summarizing the NOSES cases of nearly 100 centers in China, the study aims to clarify the current status of NOSES surgery in China. Additionally, a comprehensive analysis and summary was conducted by combining the basic information of NOSES patients, perioperative data, postoperative pathological data, and follow-up information to further demonstrate the safety and feasibility of NOSES in the treatment of colorectal cancer. This study also provides more real and objective evidence-based medicine support for the promotion and development of NOSES surgery. conditions: Colorectal Cancer studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8000 type: ESTIMATED name: Natural orifice specimen extraction measure: Rate of short-term complication measure: Operative duration measure: Intraoperative blood loss measure: Time to first flatus after surgery measure: Time to first stool after surgery measure: Length of stay after surgery measure: 3-year disease free survival measure: 3-year overall survival sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Cancer Hospital Chinese Academy of Medical Sciences status: RECRUITING city: Beijing state: Beijing zip: 100021 country: China name: Xishan Wang role: CONTACT phone: 13261967603 email: wxshan_cams@163.com name: Mingguang Zhang role: CONTACT phone: +8613261967603 email: zmgslimshady@163.com name: Xishan Wang, M.D. role: PRINCIPAL_INVESTIGATOR lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06350357 id: 2024B014 briefTitle: Conventional Clipping Versus Punching Closure overallStatus: RECRUITING date: 2024-04-01 date: 2025-12-31 date: 2025-12-31 date: 2024-04-05 date: 2024-04-05 name: Ningbo No. 1 Hospital class: OTHER briefSummary: Endoscopic submucosal dissection (ESD) is an important minimally invasive treatment method for early digestive tract tumors, with a high cure rate, and it is widely used in clinical practice. And wound closure after ESD is a great challenge, which is closely related to postoperative perforation bleeding. Clip closure is one of the most commonly used closure methods. However, when the wound is large or when the wound is located more difficult to operate, conventional closure may lead to delayed perforation, and postoperative clips may be prone to early spontaneous shedding. The authors have recently reported a method that may be able to close larger and difficult wounds because the grooves can better fix the metal clips. The latest study suggests that this approach may be safe and effective, but the study has a small sample size and has no controls. Therefore, high-quality clinical study evidence related to punch closure is required in the strategy of defect closure after ESD, in order to better evaluate the feasibility and safety of this new endoscopic closure method. conditions: the Rate of Complete Closure studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 130 type: ESTIMATED name: punching closure name: Conventional clipping measure: Completely closed measure: delayed hemorrhage sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ningbo first hospital status: RECRUITING city: Ningbo state: Zhejiang country: China name: Lei Xu role: CONTACT phone: +86-13486659126 email: xulei22@163.com lat: 29.87819 lon: 121.54945 hasResults: False
nctId: NCT06350344 id: HZKY-PJ-2024-8-2 briefTitle: Smart Technology Facilitated Patient-centered Venous Thromboembolism Management acronym: SmaVTE-COR overallStatus: NOT_YET_RECRUITING date: 2024-11-01 date: 2026-10-31 date: 2027-10-31 date: 2024-04-05 date: 2024-04-11 name: Navy General Hospital, Beijing class: OTHER briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to observe the long-term effect of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on thromboprophylaxis, and establish a foundation of evidence for managing patients with high-risk VTE. conditions: Venous Thromboembolism conditions: Digital Health conditions: Health Education studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 2353 type: ESTIMATED name: mobile venous thromboembolism application (mVTEA) measure: VTE-related composite event measure: VTE-KAP questionnaire score measure: Generic quality of life measure: VTE events measure: Major bleeding measure: VTE-related hospitalization measure: New-onset of atrial fibrillation or atrial flutter measure: Death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sixth Medical Center of Chinese PLA General Hospital city: Beijing state: Beijing zip: 100048 country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06350331 id: HZKY-PJ-2024-8-1 briefTitle: Smart Technology Facilitated Patient-centered Venous Thromboembolism Management acronym: SmaVTE-RCT overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-10-31 date: 2024-10-31 date: 2024-04-05 date: 2024-04-11 name: Navy General Hospital, Beijing class: OTHER briefSummary: Smart technologies, such as wearable devices, mobile technologies, and artificial intelligence, are being investigated for use in health management. These technologies have the potential to be applied in disease pre-warning, decision-making support, health education, and healthcare maintenance. They are expected to address the challenges in managing thrombosis, improve access to high-quality medical resources in various regions, and enhance the development of a network for thrombosis rescue and treatment prevention.
The objective of this study is to evaluate the impact of mobile venous thromboembolism application (mVTEA) based patient-centered management of venous thromboembolism (VTE) on patients' perceptions of thromboprophylaxis, in order to enhance clinical practice and establish a foundation of evidence for managing patients with VTE. conditions: Venous Thromboembolism conditions: Digital Health conditions: Health Education studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: TRIPLE whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 256 type: ESTIMATED name: mobile venous thromboembolism application (mVTEA) measure: VTE-KAP questionnaire score measure: Knowledge, attitude, and practice scores in the VTE-KAP questionnaire measure: Generic quality of life measure: VTE events measure: Chronic thromboembolic pulmonary hypertension (CTEPH) measure: Chronic thromboembolic pulmonary disease (CTEPD) measure: Post-pulmonary embolism syndrome (PPES) measure: Major bleeding measure: VTE-related hospitalization measure: VTE-related rehospitalization measure: New-onset of atrial fibrillation or atrial flutter measure: Death sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sixth Medical Center of Chinese PLA General Hospital city: Beijing state: Beijing zip: 100048 country: China name: ZHI-GENG JIN, Doctor role: CONTACT phone: 8615801402223 email: lwgjzg@163.com lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06350318 id: MCC-22005 briefTitle: Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas overallStatus: RECRUITING date: 2024-03-13 date: 2029-03 date: 2029-03 date: 2024-04-05 date: 2024-04-23 name: H. Lee Moffitt Cancer Center and Research Institute class: OTHER name: BeiGene, Ltd. briefSummary: The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas). conditions: Follicular Lymphoma conditions: Marginal Zone Lymphoma conditions: B-Cell Lymphoma studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 43 type: ESTIMATED name: Zanubrutinib name: Rituximab measure: Overall Response Rate: Cohort A measure: Overall Response Rate: Cohort B measure: Efficacy of Zanubrutinib and Rituximab measure: Safety and tolerability of combination Zanubrutinib and Rituximab sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Moffitt Cancer Center status: RECRUITING city: Tampa state: Florida zip: 33612 country: United States name: Richard Corona role: CONTACT phone: 813-745-3465 email: Richard.Corona@moffitt.org name: Sameh Gaballa, MD role: PRINCIPAL_INVESTIGATOR lat: 27.94752 lon: -82.45843 hasResults: False